The objective of the study is mapping and assessing of the effects of filaggrin mutation on atopic eczema and other atopic diseases together with serological parameters.
ID
Source
Brief title
Condition
- Epidermal and dermal conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study parameter is the prevalence of sensitisation to specific inhalant
allergens in correlation to filaggrin deficiency.
Secondary outcome
Secondary study parameters are the scores on symptom based and quality of life
questionnaires and Raman-spectral variations, reflecting variations in
molecular composition of the skin in AD.
Background summary
Filaggrin (FLG) deficiency is a key player in the pathogenesis of atopic
diseases. It is the strongest risk factor known to date for atopic dermatitis
and associated atopic march and disease specific symptoms like itch. Evidence
is building up that filaggrin deficiency causes a primary breakdown in the
epidermal barrier, which is the initial event in the development of atopic
dermatitis. Our understanding of gene- environment interactions, as the initial
event in the development of AD, should lead to a better use of some topical
products, avoidance of others, and the increased use and development of
products that can repair the skin barrier. No direct link has been made between
filaggrin deficiency and specific inhalant sensitization, itch and quality of
life before.
Study objective
The objective of the study is mapping and assessing of the effects of filaggrin
mutation on atopic eczema and other atopic diseases together with serological
parameters.
Study design
The study is designed as an exploratory cohort study in which patients with
atopic eczema deficient in filaggrin are compared to patients with atopic
eczema with sufficient levels of filaggrin.
Study burden and risks
No benefits are to be expected for the individual subjects in this study. The
risks following procedures in this study are comparable to risks the patients
are exposed to during routine care for atopic eczema.
Burg. s'' Jacobplein 51
3000 NL
NL
Burg. s'' Jacobplein 51
3000 NL
NL
Listed location countries
Age
Inclusion criteria
Patient has been diagnosed with atopic eczema by attending dermatologist
Exclusion criteria
Patient is not willing to participate
Patient does not speak or read Dutch
Patient is younger than 18 years of age
Patient can not be instructed
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL36515.078.11 |